United Therapeutics Corporation Acquires Thymmune Therapeutics

Thymmune's technology uses human-induced pluripotent stem cells (iPSCs) to create thymic cells that can mature inside the body and help restore healthy T-cell function. The thymus plays a key role in training T-cells, which are essential for a healthy immune system and for protecting the body against infections and disease.

Thymmune's lead therapy, THY-100, is currently in preclinical development for congenital athymia, a rare and life-threatening condition in which babies are born without a functioning thymus. In animal studies, THY-100 has shown the ability to create a new thymus inside the body that supports the development of healthy T-cells.

If successful in future clinical studies, THY-100 could also be used to treat other conditions, including improving organ transplant tolerance, immune-related diseases, and age-related decline in T-cell function.

Read More:TrustPoint AI Appoints Tres Seippel as Chief Innovation Officer

Under the agreement, United Therapeutics acquired Thymmune for $140 million in cash, subject to standard post closing adjustments. Former Thymmune shareholders could also receive up to $160 million in additional milestone payments if the company achieves certain clinical and regulatory goals by the end of 2031.

“Thymmune’s platform complements United Therapeutics’ broader mission to expand the supply of transplantable organs, building on our UThymoKidney™ clinical development program and our growing strength in immunomodulatory therapeutics,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. “By restoring or modulating T-cell receptor diversity, Thymmune’s technology could make fundamental contributions to human health care and potentially resolve the root causes of dozens of life-threatening diseases.”

“Thymmune was founded to harness the biology of the thymus to restore immune function for patients with serious immune-mediated diseases,” said Stan Wang, M.D., Ph.D., Chief Executive Officer and Founder of Thymmune Therapeutics. “United Therapeutics shares our conviction that regenerative medicine can transform the lives of patients, and we believe its leadership in organ alternatives and cell-based technologies makes it the ideal partner to advance our platform toward broad clinical impact.”

About United Therapeutics

Founded in 1996 by CEO Martine Rothblatt, United Therapeutics was created to find a treatment for her daughter's rare and life-threatening disease, pulmonary arterial hypertension. Today, the company develops therapies for rare diseases and works on new technologies to increase the supply of transplantable organs. It focuses on turning scientific discoveries into practical treatments that can improve and save lives.

Read More:QII Appoints Chris Kapper as Executive Vice President, Pre-Development